Drug Search Results
More Filters [+]

Capromorelin

Alternative Names: capromorelin, cp-424391, cp424391, cp 424391, cp-424,391
Latest Update: 2024-02-29
Latest Update Note: PubMed Publication

Product Description

a small molecule ghrelin receptor  (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813110/)

Mechanisms of Action: GHRH Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Capromorelin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Healthy Volunteers

Phase 1: Spinal Cord Injuries

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12614001122640

P1

Completed

Spinal Cord Injuries

2013-10-30

A257-102

P2

Terminated

Healthy Volunteers

2001-10-01

Recent News Events